Vimarsana
Biggest News Aggregation in the World

Process Development Facility News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Process Development Facility. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Process Development Facility Today - Breaking & Trending Today

CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration - Vimarsana News

CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration

/PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research,...

CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China - Vimarsana News

CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China

/PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research,...

CANbridge to Participate in Two Investor Conferences in September - Vimarsana News

CANbridge to Participate in Two Investor Conferences in September

/PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research,...

CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023 - Vimarsana News

CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023

/PRNewswire/ -- CANbridge Pharmaceuticals, Inc. ("CANbridge," stock code 1228.HK), a global biopharmaceutical company, with a foundation in China, committed to...

CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China - Vimarsana News

CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Promising Efficacy and Safety With Four-Week Extended Dosing Data Shows Dose-Dependent Reduction of LDH and Increased Hemoglobin Levels That Demonstrate Clinically Meaningful Hemolysis Inhibition CANbridge Plans to